Not everyone in the health field is so bullish on the prospects of CGMs for everyone, and question whether digging in too ...
Continuous glucose monitors (CGM), once exclusive to diabetics, are now available over-the-counter, opening new possibilities ...
Trinity Biotech today announced that it completed the first pre-pivotal clinical trial in Europe for its next-generation CGM ...
Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...
Continuous glucose monitoring enhanced by geriatric care principles reduced the duration of hypoglycemia without worsening ...
Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...
Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...
Normoglycemic individuals spent 87% of their daily time in in the “tight range” of glucose levels (70-140 mg/dL) and the remainder above 140 mg/dL.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback